These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002. DeGrendele H Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878 [No Abstract] [Full Text] [Related]
6. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831 [TBL] [Abstract][Full Text] [Related]
7. Future directions in the treatment of androgen-independent prostate cancer. Petrylak DP Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077 [TBL] [Abstract][Full Text] [Related]
8. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Petrylak DP Urology; 2005 May; 65(5 Suppl):3-7; discussion 7-8. PubMed ID: 15885271 [TBL] [Abstract][Full Text] [Related]
9. [Update of combined therapies with docetaxel for hormone-independent prostate cancer]. Li TQ; Wang JS Zhonghua Nan Ke Xue; 2008 Mar; 14(3):264-7. PubMed ID: 18488345 [TBL] [Abstract][Full Text] [Related]
10. Hormone-refractory prostate cancer: where are we going? Di Lorenzo G; Autorino R; Figg WD; De Placido S Drugs; 2007; 67(8):1109-24. PubMed ID: 17521214 [TBL] [Abstract][Full Text] [Related]
12. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. Jilani A; George E; Adler AI Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888 [No Abstract] [Full Text] [Related]
13. Recent progress in management of advanced prostate cancer. Kantoff P Oncology (Williston Park); 2005 Apr; 19(5):631-6. PubMed ID: 15945343 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for hormone-refractory prostate cancer. Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249 [TBL] [Abstract][Full Text] [Related]
15. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for metastatic castrate-sensitive prostate cancer. Miller RE; Sweeney CJ Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365 [TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
18. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004 [TBL] [Abstract][Full Text] [Related]
19. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342 [TBL] [Abstract][Full Text] [Related]